OptiBiotix Health enters MoU with Taiwan's Bened Biomedical

Josh White WebFG News | 13 Sep, 2017 16:32 | | |

calculatrice-et-trombones-comptes-entrepreneurs-entreprises-argent-finances-tpe-pme-entreprenariat-finances-banques-startup-business-plan-argent

OptiBiotix Health

70.61

10:50 22/11/17
1.60%
1.11
  • 12,445.82
  • -0.13%-16.19
  • Max: 12,476.80
  • Min: 12,402.78
  • Volume: 0
  • MM 200 : n/a
11:05 22/11/17
  • 1,024.72
  • -0.01%-0.15
  • Max: 1,026.07
  • Min: 1,024.46
  • Volume: 0
  • MM 200 : n/a
11:05 22/11/17

Life sciences business OptiBiotix Health said it has signed a memorandum of understanding with Bened Biomedical of Taiwan on Wednesday.

The AIM-traded firm said the MoU would set the framework for a “strategic partnership” to explore licensing and sales opportunities and the potential of combining relevant assets over the next 12 months.

It said Bened Biomedical was founded in 2015 as a spin-off from National Yang-Ming University by Professor Tsai, Ying-Chieh.

Bened is a leading probiotic research and marketing company, developing microbiome-based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders.

In the past two years, its flagship psychobiotic PS128 products - which reportedly help improve mental and emotional health - had been sold through both online and offline channels in more than 10 countries, generating revenues in the excess of $2m.

OptiBiotix said the MoU provided a 12-month period to explore opportunities relating to its own cholesterol and blood pressure reducing LPLDL strain and Bened's PS128, a psychobiotic that had shown encouraging results in reducing anxiety and depression in animal studies.

“We are pleased to announce this strategic partnership with Bened Biomedical and see a strong rationale for both companies to work together based on a complementary understanding of the science in different application areas of the microbiome,” said OptiBiotix chief executive officer Stephen O'Hara.

“We are excited by recent advances in psychobiotics which have the potential to address a range of mental and emotional health issues such as anxiety, depression, autism and Parkinson's.

“We strongly believe Bened's scientific and commercial capabilities in psychobiotics creates potential for OptiBiotix to bring new products to new markets and extend both our product offering and global reach in the microbiome field to bring better science and better health to all.”

Frankie Cheng, chief executive officer of Bened Biomedical, said that OptiBiotix operated in a “very exciting and progressive” area that had the potential to bring “real” health benefits.

“It has exciting products with strong science and clinical studies which we believe can be commercialised successfully through our distribution capability,” Cheng added.

“We see mutual benefit in OptiBiotix's commercial advances in Europe and US as a way to bring our PS128 product to a wider audience.”

More news

10:42 Dealogic sale to boost Euromoney cash position

International business information and events group Euromoney Institutional Investor has reached a binding agreement to sell its minority equity stake in Dealogic, a provider of content and software solutions to financial firms, to Ion Investment Group for approximately $135m, it announced on Wednesday.

10:44 Euromoney boasts strength in 'year of transition'

Business information and events group Euromoney Institutional Investor saw its revenue and profit rise comfortably in the 2017 financial year, it reported in its preliminary statement on Wednesday, with adjusted total revenue ahead 6% at £428.4m.

10:28 Pantheon International completes four new investments in October

Investment firm Pantheon International completed four new investments throughout the month of October, spreading £31.4m pounds between three existing North American interests and a new commitment towards a US mid-market buyout fund.

10:23 SSP full-year profit up, announces £100m special dividend

SSP reported a rise in full-year profit on Wednesday as it announced a special dividend of around £100m, but said that like-for-like revenue growth next year is expected to drop slightly.

09:58 Europe open: Stocks edge higher with spotlight on Fed minutes, German Socialists

Stocks have begun the morning little changed despite the strong gains overnight on Wall Street, with traders waiting for the release of the minutes of the US Federal Reserve's last rate-setting meeting in the evening and monitoring the news-flow out of Germany.

09:57 Charles Stanley warns over regulatory changes

Wealth manager Charles Stanley posted a jump in interim profit on Wednesday but cautioned that it may struggle to meet current market expectations if it does not see a higher level of trading activity or other revenue increases in the second half.

10:24 Lebanon's Hariri takes back resignation as prime minister - report

Saad al-Hariri has revoked his resignation as Lebanon's prime minister, according to a local news report on Wednesday.

09:43 Finsbury Food says trading in line, revenue up 4% in first four months

Cake and bread manufacturer Finsbury said on Wednesday that trading in the first four months of the year has been in line with expectations.

09:36 ScS hails strong start to the year

Sofa and flooring retailer ScS said on Wednesday that it has made a good start to the year.

09:26 PowerHouse reaches first milestone in waste-to-energy design

Waste-to-hydrogen production firm PowerHouse Energy has completed the pre-front-end engineering and design (pre-FEED) stage of its distributed modular gasification (DMG) system, marking the first major milestone in the design of the product.